QIAGEN N.V. today announced a broad agreement with Ares Genetics, a subsidiary of Curetis N.V. CURE, -0.10% to develop innovative bioinformatics and assay solutions to accelerate research targeting the growing global health challenges posed by antibiotic-resistant bacteria.
American Gene Technologies (AGT) recently signed a Research Collaboration Agreement with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, for research studies on AGT’s cell and gene therapy for HIV/AIDS. AGT uses its proprietary, genetically modified, autologous cell product (AGT103-T) to reconstitute the immune response against HIV with the goal of reducing persistent viral reservoirs and achieving sustained virologic remission in infected individuals in the absence of antiretroviral therapy. Under this collaboration agreement, NIAID researchers will study the mechanism of action for AGT103-T to define its potential impacts on HIV disease.
The 22-year-old firm has invested in a number of well-known local companies.
At the beginning of this decade, when the fallout of the financial crash was still being felt and traditional venture firms were struggling to raise money, the investment arms of big pharma companies stepped in to fill a funding gap that was starving start-ups. Fast forward to the current period of plenty and, while corporate cash is no longer quite so crucial to the ecosystem, many of these units remain enthusiastic backers of early-stage science.
Friday is the official last day of #HIMSS19 in Orlando. The annual healthcare conference, which began on Monday, February 11, was packed full of presentations, panels, products and people.
Wed, February 27, 2019 – 6:30 PM – 9:30 PM EST
Join us in the Washington, D.C. office of Reed Smith LLP for an engaging and interactive program discussing the implementation and commercialization in healthcare 3D printing and bioprinting applications, and the barriers associated with making this leap!
“How did you get in the robot?” That was the question a young patient at Children’s National Health System had on Thursday for Dr. Bear Bot.
Among the organizations taking glass-enclosed office space in the recently opened WeWork at University of Maryland College Park is an organization looking to promote research parks that cluster minds in science and business.
Steve Kousouris, who has been serving as Interim Executive Director of Technology Transfer at Johns Hopkins Technology Ventures since June, has assumed this role permanently effective Jan.1. Additionally, Mark Bailey, previously Associate Director of Finance, will assume responsibility for the portfolio that Steve has overseen since 2013 in the capacity of Director, Finance & Administration.
But not everything is expected to change at the Gaithersburg campus.
